Level of seven neuroblastoma-associated mRNAs detected by droplet digital PCR is associated with tumor relapse/regrowth of high-risk neuroblastoma patients.
Monitoring of several sets of neuroblastoma-associated mRNAs (NB-mRNAs) by quantitative PCR (qPCR) can be used for evaluating minimal residual disease (MRD) in neuroblastoma (NB) patients. Droplet digital PCR (ddPCR) is an adaption of qPCR that potentially provides more simple and reproducible detection of low-level of mRNAs. However, it remains tested whether MRD in NB patients can be monitored by ddPCR using a set of NB-mRNAs. In the present study, 208 bone marrow (BM) and 67 peripheral blood (PB) samples were retrospectively collected from 20 high-risk NB patients with clinical disease evaluation at two Japanese centers between 2011 and 2018, and level of each NB-mRNA (CRMP1, DBH, DDC, GAP43, ISL1, PHOX2B, and TH mRNA) was determined by ddPCR. Level of 7NB-mRNAs (defined as the combined signature of each NB-mRNA) was higher in BM than PB, but significantly correlated with each other. In accordance with disease burden, it varied with disease status (remission, stable, or progression) and collection time point (diagnosis, treatment, post-treatment, or relapse). In 73 post-treatment BM samples, it was significantly higher in 17 relapsed/regrown samples than 56 non-relapsed/non-regrown samples. Furthermore, it had a better prognostic value than qPCR detection of 7NB-mRNAs in the same 73 post-treatment BM samples. The present study suggests that ddPCR detection of 7NB-mRNAs is significantly associated with tumor relapse/regrowth of high-risk NB patients.